



Invest KOREA Market Place

Invest Korea Market Place (IKMP) is an online business matching platform available on Invest KOREA's website with information on approximately 300 Korean companies seeking to partner with foreign investors. This month, Invest Korea introduces some outstanding companies in Korea's pharmaceutical/healthcare industry.

COMPANY A



Cases of discovering virus-inhibiting factors



Cell screening process

Investment Requirement		Company Profile	
Amount	USD 100 million	Patents and Certificates	A total of 46 patents registered
Investment Structure	Equity Investment	Financial Performance	(Sales in 2020) USD 0.41 million


Investment Highlights

- Virus treatment:** The company has produced substances based on new antibody drugs with proven efficacy against various viruses by combining them with vimentin on the surface of cells using a targeted therapy method, and a treatment technology. This drug for clinical tests has been approved by the Ministry of Health of the Russian Federation for the treatment of COVID-19 patients, and is the only domestic antiviral and anti-inflammatory drug in Korea. This drug can be applied to various viral diseases because it acts on cells. It can also be applied to resistant and mutant viruses, and viruses that resist existing treatments.
- Antiviral drug market:** Threats to human health continue to increase due to outbreaks of different viruses as the global environment changes. The company forecasts that the value of the antiviral drug market will rise from USD 30.72 billion in 2020 to USD 43.37 billion in 2024, at an annual average growth rate of 9%.

COMPANY B



Existing effect



Effect of a radiation sensitizer

Investment Requirement		Company Profile	
Amount	USD 3 million	Patents and Certificates	Registered (or applied for) 3 patents at home and abroad
Investment Structure	Equity Investment	Financial Performance	(Sales in 2022, forecast) USD 4.66 million

Investment Highlights

- Radiation therapy sensitizer:** The company develops radiation sensitizers that improve the effects of radiation therapy, and is also developing a new drug that improves the effects of radiation therapy, based on technology acquired from the Korea Institute of Radiological & Medical Sciences. The drug improves the effects of chemotherapy by increasing the radio sensitivity of cells during chemotherapy. Patients can expect an excellent anticancer effect with a lower level of radiation than existing radiation treatments.
- Global anti-cancer agent market:** The number of cancer patients is increasing worldwide due to climate change and dietary change. According to the WHO UICC (Union for International Cancer Control), about 1.8 million people were diagnosed with cancer in 2018 and about 9.6 million people die of cancer every year. The global anti-cancer drug market is expected to show a high growth rate of 12.5% by 2022. According to the Korea Evaluation Institute of Industrial Technology, about 60% of cancer patients in the U.S. receive radiation therapy, and about 100,000 cancer patients are likely to receive radiation therapy every year by 2025.

For more information please e-mail ikmp@kotra.or.kr, or visit the Invest KOREA Market Place page on www.investkorea.org.